Please enable Javascript and disable ad blockers

Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Get an introduction to all features of this page

Medicines Co. Stock

Price

Target price

/ Stuttgart Stock Exchange WKN: 938858 / Symbol: MDCO / Name: Medicines / Stock / Pharmaceuticals / Mid Cap / We currently do not receive price updates for this security

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Financial data and news for Medicines

sharewise wants to provide you with the best news and tools for Medicines, so we directly link to the best financial data sources.

Financials

News

Broker

News

Meet the Biotech Stock That Just Jumped 251% Higher: https://g.foolcdn.com/editorial/images/839526/getty-happy-couple-on-couch-fistpump-smiling.jpg

Meet the Biotech Stock That Just Jumped 251% Higher

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can

0

Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its

0

BeOne Medicines (ONC) Q2 EPS Soars 924%

BeOne Medicines (ONC) Q2 EPS Soars 924%

BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue

0

Praxis (PRAX) Q2 Loss Widens 90%

Praxis (PRAX) Q2 Loss Widens 90%

Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company specializing in therapies for central nervous system (CNS) disorders. On August 4, 2025, it reported financial

0